AN2 Therapeutics, Inc. reports clinical-stage biopharmaceutical developments tied to novel small-molecule therapeutics derived from its boron chemistry platform. Company updates center on infectious-disease programs such as Chagas disease, NTM lung disease caused by Mycobacterium abscessus and melioidosis, along with oncology, hematologic-disease and other research programs.
Recurring ANTX news includes clinical and regulatory updates for candidates such as epetraborole and AN2-502998, investigator-initiated trial activity, operating and financial results, material agreements, governance matters and investor conference participation.
AN2 Therapeutics (ANTX) granted inducement equity awards to two newly hired employees on October 19, 2026, under its employment inducement plan. The awards comprise options to purchase 10,565 common shares at an exercise price of $3.37 per share and 5,283 restricted stock units (RSUs).
One quarter of the options vest on the first anniversary of the vesting commencement date, followed by 1/48th each month. RSUs vest annually over four years, subject to continuous service. The Compensation Committee approved the awards under Nasdaq Listing Rule 5635(c)(4).
AN2 Therapeutics (ANTX) will present its planned Phase 2 epetraborole trial design at a poster session on October 29, 2026. The study will evaluate oral epetraborole in patients with phlebotomy-dependent polycythemia vera, who require blood removal to manage their disease. The presentation is scheduled for 5:45–7:15 p.m. ET at the 18th International Congress on Myeloproliferative Neoplasms in Brooklyn, New York, as poster 148.
AN2 Therapeutics (ANTX) announced that its management will participate in three investor conferences in November 2026, including presentations by CEO Eric Easom.
Easom will join a fireside chat at the Guggenheim Healthcare Innovation Conference on November 9 at 9:30am ET and give a corporate overview at the Stifel Healthcare Conference on November 10 at 8:40am ET. Management will be available for one-on-one meetings at both conferences and at the Jefferies London Conference on November 17. Webcasts will be available through the company's investor website, with archived replays available for at least 30 days following the presentation.
AN2 Therapeutics (ANTX) received an extension of Gates Foundation funding for its tuberculosis research collaboration with GSK. The funding supports AN2’s work on boron-based inhibitors of leucyl-tRNA synthetase (LeuRS), an enzyme the collaboration is targeting in its search for potential treatments.
LeuRS is also the target of ganfeborole, which demonstrated proof-of-concept efficacy in a Phase 2 tuberculosis study. Other drugs targeting the enzyme include epetraborole, in development for M. abscessus lung disease, and tavaborole, an FDA-approved antifungal. The AN2–GSK work remains a research collaboration.
AN2 Therapeutics (ANTX) granted inducement equity awards to newly appointed Chief Medical Officer Cameron Trenor, M.D., under Nasdaq Listing Rule 5635(c)(4), with a grant date of September 15, 2026.
The awards comprise a non-qualified stock option for 233,333 shares and restricted stock units (RSUs) for 116,667 shares of common stock. The option exercise price is $5.36 per share, equal to the closing price on the grant date, and the option has a 10-year term. Option vesting occurs over four years: 25% on August 24, 2026, the one-year anniversary of Dr. Trenor’s hire date, and the remainder monthly over the following three years. Of the RSUs, 10,400 vest on January 1, 2027, with the balance vesting in approximately three equal annual installments starting January 1, 2028, subject to continued service. The awards were issued under AN2’s 2026 Employment Inducement Award Plan.
AN2 Therapeutics (Nasdaq: ANTX) reported that four abstracts featuring clinical and nonclinical data on epetraborole, a boron-containing oral candidate for polycythemia vera (PV), will be presented at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting, held September 9‑12, 2026, in Houston, Texas.
According to AN2 Therapeutics, the abstracts describe potential beneficial effects of epetraborole on erythropoiesis and hemoglobin-related parameters, along with hematological and safety data across healthy volunteers, non-PV patients, and nonhuman primate models. Exposure‑response relationships observed in nonhuman primates were reported to predict effects later seen in humans, supporting the translational value of these models and the ongoing clinical development of epetraborole as a potential oral PV treatment.
AN2 Therapeutics (Nasdaq: ANTX) has appointed Cameron Trenor, M.D., as Chief Medical Officer, adding more than 20 years of clinical, translational and drug development leadership experience across hematology, rare diseases, oncology, immunology and metabolic disorders. According to AN2 Therapeutics, Dr. Trenor has led programs from discovery through global clinical development, regulatory interactions and commercialization planning.
He previously served as CMO of Cellarity, overseeing its first IND and global first-in-human study, and as Executive Medical Director at Forma Therapeutics, where he led development of etavopivat into Phase 3. Co-founder George H. Talbot, M.D., who led AN2’s clinical programs over the last two years, will continue as senior scientific advisor and strategic advisor during the transition.
AN2 Therapeutics (Nasdaq: ANTX) reported Q2 2026 R&D expenses of $6.0 million and G&A expenses of $2.9 million, leading to a net loss of $8.2 million. Cash, cash equivalents and investments totaled $79.9 million, which the company projects will fund operations into 2029.
AN2 is advancing three Phase 2 programs: a global proof-of-concept trial of oral epetraborole in polycythemia vera with IND filing expected in Q3 2026 and enrollment in Q4 2026; an ongoing 84-patient investigator-initiated Phase 2 trial of epetraborole in M. abscessus lung disease with topline data anticipated in late 2027; and a Phase 2 proof-of-concept study of AN2-502998 in chronic Chagas disease planned for late 2026, supported by 100% parasitic elimination in a non-human primate study and a generally well-tolerated Phase 1 profile.
The company also declared an ENPP1 development candidate for solid tumors and expects to advance a second boron-based oncology candidate by year-end 2026.
AN2 Therapeutics (Nasdaq: ANTX) reported enabling data for its oral CPSF3 inhibitor AN2-502998 in chronic Chagas disease. In nonhuman primates with naturally acquired chronic T. cruzi infection, 28 days of treatment achieved 100% parasite elimination, durable to four months. A Phase 1 study showed AN2-502998 was generally well tolerated with no dose-limiting toxicities and human exposures meeting nonhuman primate efficacy thresholds, supporting advancement to a planned Phase 2 proof-of-concept trial and highlighting a potential multi-billion-dollar U.S. and global commercial opportunity, including possible FDA Tropical Disease Priority Review Voucher eligibility if approved.
AN2 Therapeutics (Nasdaq: ANTX) announced that Co-Founder, Chairman, President and CEO Eric Easom will present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 12:50 PM ET.
Management will also host 1x1 meetings, and a webcast and 30-day replay will be available via the investor relations website.